Want to see IN:AARTIPHARM full AI Analyst Report?
AARTIPHARM Stock Chart & Stats
₹842.40
₹9.55(1.45%)
At close: 4:00 PM EST
₹842.40
₹9.55(1.45%)
Day’s Range― - ―
52-Week Range₹583.85 - ₹946.45
Previous CloseN/A
Volume141.60K
Average Volume (3M)18.67K
Market Cap
₹78.22B
Enterprise Value₹81.13K
Total Cash (Recent Filing)₹96.16M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)36.7
Beta0.81
Next Earnings
Nov 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.46%
Share Statistics
EPS (TTM)23.51
Shares Outstanding90,679,810
10 Day Avg. Volume12,195
30 Day Avg. Volume18,670
Financial Highlights & Ratios
PEG Ratio-0.92
Price to Book (P/B)2.71
Price to Sales (P/S)3.16
P/FCF Ratio-30.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulated API FocusAarti Pharmalabs' core business is manufacturing regulated APIs and high-purity intermediates, which requires compliance, customer qualification and quality systems. Those factors create higher entry barriers, longer customer relationships and structural demand from pharma supply chains over months to years.
Historical Margin StrengthThe company showed consistently healthy operating and net margins through FY2023–FY2025, indicating efficient processes and pricing power in core molecules. Sustainable margins provide a buffer against raw-material volatility and enable reinvestment into capacity or compliance over the medium term.
Positive Operating Cash FlowDespite swings in free cash flow, operating cash flow has been positive, signaling underlying cash-generative operations. Reliable operating cash provides medium-term flexibility to fund working capital, service debt, and prioritize capex for capacity or quality upgrades if management maintains discipline.
Bears Say
Recent Revenue DeclineA ~4.5% revenue decline and sharply lower net income in FY2026 represent a clear weakening in demand or pricing for the company's molecules. If this trend persists, it undermines cash generation, pressures margins and complicates medium-term planning for capacity and contract commitments.
Rising LeverageA material step-up in borrowings in FY2026 reduces balance-sheet flexibility and raises interest and refinancing risk. With profitability under pressure, higher leverage meaningfully increases vulnerability to cash-flow shocks and limits the firm's ability to fund strategic investments without raising external capital.
Negative Free Cash FlowSustained negative free cash flow across FY2025–FY2026 suggests elevated capex or working-capital strain consuming operating cash. Continued negative FCF forces dependence on debt or equity financing, heightening liquidity and execution risk over the coming months if cash conversion isn't restored.
Aarti Pharmalabs Limited News
AARTIPHARM FAQ
What was Aarti Pharmalabs Limited’s price range in the past 12 months?
Aarti Pharmalabs Limited lowest stock price was ₹583.85 and its highest was ₹946.45 in the past 12 months.
What is Aarti Pharmalabs Limited’s market cap?
Aarti Pharmalabs Limited’s market cap is ₹78.22B.
When is Aarti Pharmalabs Limited’s upcoming earnings report date?
Aarti Pharmalabs Limited’s upcoming earnings report date is Nov 09, 2026 which is in 81 days.
How were Aarti Pharmalabs Limited’s earnings last quarter?
Aarti Pharmalabs Limited released its earnings results on Aug 07, 2026. The company reported ₹8.397 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Aarti Pharmalabs Limited overvalued?
According to Wall Street analysts Aarti Pharmalabs Limited’s price is currently Overvalued.
Does Aarti Pharmalabs Limited pay dividends?
Aarti Pharmalabs Limited pays a Semiannually dividend of ₹2 which represents an annual dividend yield of 0.46%. See more information on Aarti Pharmalabs Limited dividends here
What is Aarti Pharmalabs Limited’s EPS estimate?
Aarti Pharmalabs Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aarti Pharmalabs Limited have?
Aarti Pharmalabs Limited has 90,679,810 shares outstanding.
What happened to Aarti Pharmalabs Limited’s price movement after its last earnings report?
Aarti Pharmalabs Limited reported an EPS of ₹8.397 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.732%.
Which hedge fund is a major shareholder of Aarti Pharmalabs Limited?
Currently, no hedge funds are holding shares in IN:AARTIPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides contract development and manufacturing services for drug substance projects. In addition, the company offers intermediates; xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline; and acid and allied products, including sulphuric acid, sulphur trioxide, oil, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is headquartered in Mumbai, India.
Technical Analysis
Bliss Gvs Pharma Limited
―
FDC Ltd.
―
Gufic Biosciences Limited
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Orchid Pharma Limited
―